11 January 2019 | News
Medigen Biotech will use CellMax Life’s circulating tumor cell platform CMxTM, in combination with its comprehensive liquid biopsy panel.
CellMax Life, a US based diagnostics company with a proprietary technology to detect precancer and cancer cells in blood, has been named as a partner in Taiwan based Medigen Biotech’s upcoming cell therapy clinical trials. Medigen Biotech will use CellMax Life’s circulating tumor cell platform CMxTM, in combination with its comprehensive liquid biopsy panel to assess treatment selection and response.
The planned open-label, multi-center, single arm clinical trial is expected to enroll patients with Stage II and III colorectal cancer that has been surgically resected, or surgically resected and treated with chemotherapy. For the phase I trial, expected to initiate in 2019, patients who test positive on the CellMax Life blood test will receive the NK cell therapy. This trial is designed to monitor patients multiple times during the course of treatment, using the CellMax blood test, to assess treatment response.
CellMax Life's proprietary blood test uniquely isolates and analyzes both circulating tumor cells and circulating tumor DNA from a single sample of blood for the assessment of six types of analytes including four classes of genomic alterations, micro-satellite instability and circulating tumor cells.